Pharmaceuticals UK

UK Myasthenia Gravis Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

UK Myasthenia Gravis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UK · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $73.9 Mn Placeholder estimate
Estimate 2025 $83.7 Mn 2.5% of the global market
Projected 2034 $255.4 Mn 205.2% Adds $171.7 Mn over 9 forecast years
CAGR 2025–2034 13.2% Faster than 78% of 180 Pharmaceuticals markets here
Key players 5
  • UK is 2.53% of the global market.
  • In Europe, the largest is Germany at $110.9 Mn.
  • Fastest growing: Russia at 14.8% a year.
  • UK ranks 2nd of 6 by size in Europe.

Market size projection

UK

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$171.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Myasthenia Gravis Treatment Market market size by year, UK
YearMarket sizeChange that yearSince 2025
2024 (estimate) $73.9 Mn — —
2025 (base) $83.7 Mn +$9.8 Mn —
2026 (forecast) $94.7 Mn +$11.0 Mn +13.2%
2027 (forecast) $107.2 Mn +$12.5 Mn +28.1%
2028 (forecast) $121.4 Mn +$14.2 Mn +45.1%
2029 (forecast) $137.4 Mn +$16.0 Mn +64.2%
2030 (forecast) $155.5 Mn +$18.1 Mn +85.9%
2031 (forecast) $176.1 Mn +$20.5 Mn +110.4%
2032 (forecast) $199.3 Mn +$23.2 Mn +138.2%
2033 (forecast) $225.6 Mn +$26.3 Mn +169.6%
2034 (forecast) $255.4 Mn +$29.8 Mn +205.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

UK Myasthenia Gravis Treatment Market Analysis at a glance
Market size, 2025$83.7 Mn placeholder estimate
Forecast, 2034$255.4 Mn placeholder estimate
Growth (CAGR), 2025–203413.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersargenx, AstraZeneca, UCB, Johnson & Johnson, Amgen Inc. (see all)
Regulator in the UKMHRASource: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials19 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UK Myasthenia Gravis Treatment Market Analysis Executive Summary

Myasthenia gravis treatments improve muscle weakness in this autoimmune nerve-muscle disease, including new FcRn and complement blockers.

Key segments of the myasthenia Gravis Treatment market include drug class (FcRn Blockers, Complement Inhibitors and Cholinesterase Inhibitors) and route (Oral, Intravenous and Subcutaneous).

Bar chart: UK Myasthenia Gravis Treatment market size, 2024–2034, placeholder estimates. $73.9 Mn in 2024, $83.7 Mn in 2025 and $255.4 Mn in 2034, 13.2% CAGR.
UK Myasthenia Gravis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UK Myasthenia Gravis Treatment Market Dynamics

Market Growth Drivers

More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the myasthenia Gravis Treatment market. Biosimilars are widening access.

Opportunity

New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the myasthenia Gravis Treatment market room to grow.

Market Restraints

High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the myasthenia Gravis Treatment market.

Competitive Landscape for Myasthenia Gravis Treatment Market in the UK

The myasthenia Gravis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Myasthenia Gravis Treatment Market in the UK

Myasthenia Gravis Treatment in the UK: rules, payment and research

The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK.⁠[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.⁠[2] ClinicalTrials.gov lists 19 studies on Myasthenia Gravis Treatment that are recruiting, active or about to start in the UK.⁠[3]

[1] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[2] National Institute for Health and Care Excellence. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for myasthenia Gravis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in the UK.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Myasthenia Gravis Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Myasthenia Gravis Treatment in context

The UK compared

  • Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 7th highest of the 13 countries we cover in Europe.[1]
  • Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 11th highest of the 13 countries we cover in Europe.[2]
  • People aged 65 and over: 19.7% of people (2025). World: 10.4% of people (2025). 11th highest of the 13 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Inside the UK

Quick answers

Frequently asked questions

How big is the Myasthenia Gravis Treatment market in the UK?
Placeholder estimate: about $83.7 Mn in 2025, rising to about $255.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Myasthenia Gravis Treatment market in the UK growing?
Placeholder estimate: about 13.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Myasthenia Gravis Treatment market report cover?
The report splits the market by drug class (FcRn Blockers, Complement Inhibitors, Cholinesterase Inhibitors, Immunosuppressants), route (Oral, Intravenous, Subcutaneous) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Myasthenia Gravis Treatment market?
Key players include argenx, AstraZeneca, UCB, Johnson & Johnson and Amgen Inc..
What is driving the Myasthenia Gravis Treatment market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the myasthenia Gravis Treatment market. Biosimilars are widening access.
Who regulates Myasthenia Gravis Treatment in the UK?
The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK. Source: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in the UK?
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Myasthenia Gravis Treatment are running in the UK?
19 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
How much research is published on Myasthenia Gravis Treatment?
PubMed lists 24 papers on Myasthenia Gravis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in UK

See all

Related on autoimmune diseases and brain and nerves

See the topic